InMed Pharmaceuticals Inc. ("InMed") (CSE: IN; OTCQB: IMLFF) announces it has formed an exclusive strategic collaboration with the University of Debrecen, Hungary, to develop novel phytocannabinoid-based therapies to treat ocular allergic symptoms. The collaboration will leverage InMed's proprietary Intelligent Cannabinoid Drug Design Platform (IDP) and will be led by one of the world's leading cannabinoid researchers, Dr. Tamas Biro, MD, PhD, DSc. Dr. Biro has extensive research experience in studying the endocannabinoid system (ECS) and the closely related transient receptor potential (TRP) channels in various human diseases.
Under the discovery and development collaboration InMed's IDP Platform will be used to identify cannabinoid- and non-cannabinoid-based phytochemicals for ocular therapies focused on reducing various pro-inflammatory cytokines in in vitro and in vivo models.
Dr. Sazzad Hossain, Chief Scientific Officer of InMed, stated, "We have accumulated significant experience and expertise in developing cannabinoids to treat ocular disease, which forms the basis of this strategic collaboration. As we prepare to initiate Phase 1 clinical trials of our lead phytocannabinoid-based drug candidate CTI-085 for glaucoma, we look forward to expanding our ophthalmic therapy pipeline by developing ocular anti-allergic drugs, where we expect Dr. Biro's 18 years of experience in this specialty field to be invaluable."
"The global ocular allergy space is a multi-billion dollar market and our platform offers a novel approach to potentially treating a wide array of allergies," said Craig Schneider, President and CEO of InMed. "We are excited to move a lead candidate toward preclinical and clinical trials and will provide additional updates as they become available."
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain